EXC vs LXRX · P/E 17, rev $24.26B vs rev $21.8M
Exelon Corporation (EXC) versus Lexicon Pharmaceuticals Inc (LXRX) — a side-by-side from cached financials, not a winner call.
Exelon Corporation (EXC) is a utilities - regulated electric company listed on NASDAQ.
Lexicon Pharmaceuticals Inc (LXRX) is a biotechnology company listed on US.
Latest reported EXC revenue for 2025-12-31 was $24.26B. Net income was $2.77B. Revenue was up 5.3% from 2024-12-31 to 2025-12-31. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
Latest reported LXRX revenue for 2026-06-30 was $21.8M. Net income was -$32.8M. Revenue was up 3.3% from 2026-03-31 to 2026-06-30. LXRX currently screens at market cap $327.2M.
EXC currently screens at market cap $47.33B and trailing P/E 16.8. LXRX currently screens at market cap $327.2M.
Not investment advice. Open the EXC and LXRX stock pages for the full models.
Not investment advice.